Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
暂无分享,去创建一个
Richard Pazdur | Huanyu Chen | P. Keegan | R. Pazdur | Hong Zhao | Martin H. Cohen | Stacy Shord | Hong Zhao | Martin H Cohen | Kun He | Patricia Keegan | S. Shord | Huanyu Chen | Chana Fuchs | Sharon Sickafuse | C. Fuchs | Kun He | S. Sickafuse | M. Cohen
[1] C. Bokemeyer,et al. Patients and Methods: the European Organisation for Research and Treatment of Cancer Qol Questionnaire , 2022 .
[2] J. Baselga,et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Ruth Katz,et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.
[4] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[5] F Demard,et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas , 1991, Head & neck.
[6] A. Schueler,et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Jordi Giralt,et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.
[8] Christine H Chung,et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Frampton. Cetuximab , 2010, Drugs.
[10] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[11] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[12] J. Vermorken,et al. Cetuximab in the treatment of squamous cell carcinoma of the head and neck , 2011, Expert review of anticancer therapy.
[13] W. Hong,et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] F. Rivera,et al. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial , 2009, Expert review of anticancer therapy.